SS-31 99% purity factory direct sales Low price High Quality Fast Delivery and Great Prices | Youngshe
TDS 3 Inquiries
000000-00-0
Pharmaceutical Grade
99%
Chengdu
Chengdu Youngshe Chemical Co.,Ltd
1g/bottle, 10g/bottle,100g/bottle
2029-12-28
Peptide,Custom Peptide,KPV,MOTS-c,DSIP
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionCertificates
-
TDS
Basic Info-
Product Name:
valium
CAS No.:000000-00-0
Categories:
Research-
Class:
Mitochondria-targeted tetrapeptide (Szeto-Schiller peptide)
Status:FDA-approved (Forzinity) — Accelerated Approval 2025
Mechanism:A cell-permeable, synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH₂) that selectively concentrates in the inner mitochondrial membrane and reversibly binds to cardiolipin, a phospholipid essential for electron transport chain (ETC) function. By stabilizing cardiolipin, SS-31 restores mitochondrial bioenergetics, reduces cytochrome c peroxidase activity, and prevents oxidative damage in cells with impaired mitochondrial function.
Activity note:SS-31 does not act via traditional receptor agonism. It binds cardiolipin with high selectivity in the inner mitochondrial membrane. Functional EC₅₀ values are context-dependent (cell type, stress model). Key electrophysiology studies report mitochondrial membrane potential restoration at nanomolar concentrations.
Source:Szeto HH, et al. AAPS J. 2006;8(2):E277-E283. Birk AV, et al. J Am Soc Nephrol. 2014;25(6):1157-1169.DOI
Clinical Development:FDA:Forzinity (approved 2025-09-19)
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Literature:
FDA: Forzinity (NDA 215244) — Accelerated Approval 2025; Genetics in Medicine: TAZPOWER Phase 2/3 results (Thompson et al. 2020); Drugs: Elamipretide First Approval (Springer 2025)
Disclaimer:Elamipretide (Forzinity) is FDA-approved under accelerated approval for Barth syndrome. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Peptide,Custom Peptide,KPV,MOTS-c,DSIP
-
Location:
Chengdu
-
Average lead Time:
10
-
Total Annual Revenue:
$50 million-$100 million
-
Total Employees:
11-50
-
Year of Establishment:
2015
-
-
Inquiry History3 Inquiries
Country Product Purchase Quantity Date Posted 
Canada
bio requlators
100 MT Oct 31, 2024 
United States
Tesofensine 500mcg
100 PCS Oct 7, 2025 
Australia
Sodium Nitroprusside, Potassium Nitrite, Ammonium Metavanadate, Selenious Acid, & 1,3-Dinitrobeneze
1 Aug 3, 2024 Post an enquiry for this product
